DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Regulatory Request NIS in Korea

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: JARDIANCE DUO®

First Posted Date: 2018-08-22

Last Posted Date: 2021-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 658

Registration Number: NCT03642717

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of

and more 17 locations

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: BI 50 mg (fasted)
Drug: BI 100 mg (fasted)
Drug: BI 200 mg (fasted)
Drug: Placebo (fed)
Drug: BI 400 mg once daily (fed)
Drug: BI 200 mg twice daily, 400 mg total (fed)
Drug: Placebo (fasted)
Drug: BI 25 mg (fasted)

First Posted Date: 2018-08-17

Last Posted Date: 2022-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT03635099

Locations: 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 30 locations

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)
Drug: Empagliflozin
Drug: Linagliptin
Drug: Metformin HCl

First Posted Date: 2018-08-14

Last Posted Date: 2020-02-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT03629054

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: T1 - Low dose of BI 655130
Drug: T2 - Low dose of BI 655130
Drug: T3 - High dose of BI 655130
Drug: R - Low dose of BI 655130

First Posted Date: 2018-08-06

Last Posted Date: 2024-03-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT03617835

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Inhaled corticosteroid

First Posted Date: 2018-08-02

Last Posted Date: 2021-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 901

Registration Number: NCT03611777

Locations: 🇪🇸
CS Las Cabezas de San Juan, Las Cabezas, Sevilla, Spain
🇪🇸
CS Virgen de la Estrella 2, Coria Del Río, Sevilla, Spain
🇪🇸
CS Puebla de Cazalla, Puebla De Cazalla, Sevilla, Spain

and more 165 locations

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517
Drug: Placebo

First Posted Date: 2018-07-31

Last Posted Date: 2024-11-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT03608072

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: BI 905677

First Posted Date: 2018-07-27

Last Posted Date: 2024-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT03604445

Locations: 🇳🇱
Erasmus MC Kanker Instituut, Rotterdam, Netherlands
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

and more 2 locations

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Empagliflozin
Drug: Matching placebo

First Posted Date: 2018-07-20

Last Posted Date: 2025-02-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6609

Registration Number: NCT03594110

Locations: 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇨🇦
CHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada
🇨🇦
CHU de Quebec-Universite Laval Research Centre, Quebec, Canada

and more 234 locations

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: BI 456906

First Posted Date: 2018-07-19

Last Posted Date: 2021-03-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 131

Registration Number: NCT03591718

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Germany

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495
Drug: Placebo

First Posted Date: 2018-07-17

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT03588390

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy